by Ryan Michalek | Apr 16, 2025 | Press Releases
Elusys Therapeutics Commends U.S. Congress for Introduction of H.R. 2707, Bolstering Anthrax Preparedness Urges Swift Passage of H.R. 2707, the First Standalone Anthrax Preparedness Legislation in Over a Decade Parsippany, NJ, Boca Raton, FL and Research Triangle...
by Ryan Michalek | Jul 22, 2022 | Press Releases
Elusys Invited to Present LAV-BASTA-48 Anthrax Vaccine at the Annual Defense Threat Reduction Agency (DTRA) Chemical and Biological Science & Technology Annual Conference Live Attenuated Single-Dose Spore-Based MDR-Anthrax Vaccine elicits protective immunity for...
by Ryan Michalek | Jul 22, 2022 | Press Releases
Elusys Executes Initial Procurement Contract to Deliver ANTHIM® to the Canadian Government New contract marks the first international sale of ANTHIM® PARSIPPANY, N.J., April 27, 2022 – Today Elusys Therapeutics annoucned it has finalized a contract with the Canadian...
by Admin | Jul 14, 2022 | Press Releases
ELUSYS THERAPEUTICS RECEIVES HEALTH CANADA APPROVAL FOR ANTHIM® FOR THE TREATMENT OF INHALATION ANTHRAX PARSIPPANY, NJ, AUGUST 12, 2020 – Elusys Therapeutics, Inc. (Elusys) today announced that Health Canada has approved the company’s New Drug Submission (NDS) for...
by Admin | Jul 14, 2022 | Press Releases
OBILTOXAXIMAB RECEIVES POSITIVE CHMP OPINION FOR THE TREATMENT OF INHALATION ANTHRAX European Commission Decision Anticipated in November 2020 PARSIPPANY, NJ, OCTOBER 8, 2020 – Elusys Therapeutics, Inc. (Elusys) today announced that the Committee for Medicinal...
by Admin | Jul 14, 2022 | Press Releases
OBILTOXAXIMAB RECEIVES MARKETING AUTHORIZATION FROM EUROPEAN COMMISSION FOR THE TREATMENT OF INHALATION ANTHRAX PARSIPPANY, NJ, DECEMBER 2, 2020 – Elusys Therapeutics, Inc. (Elusys) today announced that the European Commission has approved obiltoxaximab, the company’s...
